Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Patent metadata

Field	Value
Publication number	US-12202891-B2
Application number	US-202418607180-A
Country	US
Kind code	B2
Filing date	Mar 15, 2024
Priority date	Jun 4, 2019
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

First claim

What is claimed is:

1. An anti-thymic stromal lymphopoietin (anti-TSLP) antibody comprising a heavy chain variable region and a light chain variable region, wherein:
(i) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 26, SEQ ID NO: 94 and SEQ ID NO: 28, respectively; and,
(ii) the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 29, SEQ ID NO: 113 and SEQ ID NO: 31, respectively.

2. The anti-TSLP antibody according to claim 1 , wherein the anti-TSLP antibody is a murine antibody, a chimeric antibody, or a humanized antibody.

3. The anti-TSLP antibody according to claim 1 , wherein the amino acid sequence of the heavy chain variable region comprises the sequence of SEQ ID NO: 97, and the amino acid sequence of the light chain variable region comprises the sequence of SEQ ID NO: 119.

4. The anti-TSLP antibody according to claim 3 , wherein the antibody further comprises an antibody heavy chain constant region and a light chain constant region; wherein the heavy chain constant region is selected from the group consisting of human IgG1, IgG2, IgG3 and IgG4 constant regions; and wherein the light chain constant region is selected from the group consisting of human antibody κ (kappa), human antibody λ (lambda) chain constant regions.

5. The anti-TSLP antibody according to claim 4 , wherein the antibody comprises a heavy chain constant region as shown in SEQ ID NO: 133, and comprises a light chain constant region as shown in SEQ ID NO: 134.

6. An anti-TSLP antibody comprising:
(i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 97;
(ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 119;
iii) a human IgG1 heavy chain constant region; and,
(iv) a light chain constant region that is selected from the group consisting of a human κ (kappa) light chain constant region, λ (lambda) light chain constant region.

7. The anti-TSLP antibody according to claim 6 , wherein the antibody comprises a heavy chain constant region as shown in SEQ ID NO: 133, and a light chain constant region as shown in SEQ ID NO: 134.

8. A pharmaceutical composition containing a therapeutically effective amount of the anti-TSLP antibody according claim 1 and one or more pharmaceutically acceptable carriers, diluents, buffers, or excipients.

9. An anti-thymic stromal lymphopoietin (anti-TSLP) antibody comprising: a heavy chain comprising the amino acid as shown in SEQ ID NO: 139, and a light chain comprising the amino acid sequence as shown in SEQ ID NO: 140.

Assignees

• Jiangsu Hengrui Medicine Co
• Shanghai hengrui pharmaceutical co ltd

Inventors

• Shi Jinping
• Ying Hua
• Li Tingting
• Wang Yifang
• Yang Guimei
• Ge Hu
• Tao Weikang

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/505

  comprising antibodies · CPC title